BR1019C-1

Phase 3Small molecule

Boryung Pharmaceutical Co., Ltd

BR1019C-1 is one of 45 small molecule programs targeting Combination Therapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Combination TherapyRecruiting

Combination TherapyPhase 3

Recruiting

Competition

Competitive Landscape

56 competitors in Combination Therapy

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

1 2

Ritalin

Novartis

Phase 3

1 3

Avastin

Roche

Phase 2

5 4

Liposomal Doxorubicin

Eli Lilly

Phase 3

1 5

Keytruda

Merck & Co.

Phase 2

3 6

Taxol

Teva

Phase 2

3 7

Beyfortus

BeiGene

Phase 2

3 8

Gleevec

Novartis

Phase 2

2 9

Braftovi

Pfizer

Phase 2

1 10

Cabometyx

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Combination Therapy1 trial

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

Recruiting· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT06220773·276 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BR1019C-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BR1019C-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BR1019C-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boryung Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boryung Pharmaceutical Co., Ltd

BR1019C-1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Combination Therapy1 trial

References

Drug Info

Quick Facts

Related News